A study published in the online Scientific Reports journal reveals a new maladaptive and pro-inflammatory effect of adiponectin – its ability to increase T helper (Th)17 immune responses and the expression of receptor activator of nuclear factor-κB ligand (RANKL) in an animal model of arthritis.
Both pro-and anti- inflammatory effects of adiponectin have been described. Interestingly, low levels of adiponectin in obesity, type II diabetes, and metabolic disorders, but high levels of adiponectin are reportedin heart failure, hypertension, and chronic inflammatory and autoimmune diseases such as systemic lupus erythematosus, type I diabetes and rheumatoid arthritis (RA).
In the Scientific Reports study, Xiaoxuan Sun and colleagues from the Department of Rheumatology and Immunology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, China, studied the role of adiponectin, the link between RANKL, IL-17 and bone erosion in mice with collagen-induced arthritis (CIA).
The authors report that local adiponectin, IL-17 and RANKL levels are increased during CIA development. Furthermore, the intra-articular injection of adiponectin into the knee joint of CIA animals aggravates arthritic progression and bone erosion, accompanied by an increased number of Th17 cells and a high expression of RANKL in joint tissues.
Importantly, the researchers provide evidence that adiponectin most likely is able to promote the Th17 cell differentiation through up-regulation of ROR-γt, IL-22 and IL-23 expression.
It appears that this study identifies a novel maladaptive role of adiponectin, namely, the promotion of local and highly pathogenic Th17 cell immune responses in experimental arthritis.
The authors conclude that their study suggests that in arthritis, the locally increased adiponectin levels may contribute to inflammation and bone erosion by enhancing Th17 responses and RANKL expression.